10th February, 2026

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that a Pre-Approval Inspection (PAI) was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals, Inc. ("InvaGen"), a wholly owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, from 2nd February, 2026 to 9th February, 2026.

On conclusion of the inspection, InvaGen has received 2 (two) inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

RAJENDRA CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2026.02.10 08:36:17 +05'30'

Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani